title: Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: a double-blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover.
abstract: Immobilization is associated with increased bone resorption and decreased bone formation. We evaluated in a double-blind trial the effect of intranasal administration of salmon calcitonin on biochemical parameters of bone turnover in 32 patients immobilized for a prolapsed intervertebral disk. Calcitonin in a dose of two times 200 IU/day partially inhibited the increase in the fasting 2 h urinary hydroxyproline/creatinine ratio (OHPr/Cr) and calcium/creatinine ratio (Ca/Cr). The increase in OHPr/Cr was 40% less in the calcitonin group compared to the placebo group (P = 0.01), and the increase in Ca/Cr was 80% less in the calcitonin group (P = 0.04). Calcitonin also partially inhibited the increase in serum cross-linked carboxyl-terminal telopeptide of collagen type I (P < 0.05). The decrease in serum 1,25-dihydroxyvitamin D after 10 days of immobilization was significantly less in the calcitonin-treated group than in the placebo group (14 versus 29%, respectively; P < 0.05). Intranasal calcitonin did not influence the pain scores as measured with a visual analog scale (VAS). The tolerability of the nasal calcitonin preparation was excellent. We conclude that nasal salmon calcitonin counteracts the early increase in bone resorption induced by immobilization.
authors.affiliation: Department of Endocrinology, Free University Hospital, Amsterdam.
authors.forename: H E
authors.initials: HE
authors.lastname: van der Wiel
authors.forename: P
authors.initials: P
authors.lastname: Lips
authors.forename: J
authors.initials: J
authors.lastname: Nauta
authors.forename: G
authors.initials: G
authors.lastname: Kwakkel
authors.forename: G
authors.initials: G
authors.lastname: Hazenberg
authors.forename: J C
authors.initials: JC
authors.lastname: Netelenbos
authors.forename: W J
authors.initials: WJ
authors.lastname: van der Vijgh
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D001510:Bed Rest / Q000009:adverse effects; D001862:Bone Resorption / Q000517:prevention & control*; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D002116:Calcitonin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002118:Calcium / Q000652:urine; D003094:Collagen / Q000097:blood; D024042:Collagen Type I; D003404:Creatinine / Q000652:urine; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007103:Immobilization / Q000009:adverse effects*; D007405:Intervertebral Disc Displacement / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010455:Peptides / Q000097:blood
chemical_list: D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; C028815:salmon calcitonin; D002116:Calcitonin; D003094:Collagen; D003404:Creatinine; D006909:Hydroxyproline; D002118:Calcium